We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Xoma's Gevokizumab Fails Phase III Trial

News   Jul 23, 2015

 
Xoma's Gevokizumab Fails Phase III Trial
 
 
 

RELATED ARTICLES

New Regulators of Macrophage Pyroptosis

News

Two enzymes, TAK1 and IKK, have been identified as important kinases involved in the regulation of pyroptosis - a highly inflammatory form of programmed cell death, which often forms part of the antimicrobial response.

READ MORE

Statins Have Low Risk of Side Effects

News

The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.

READ MORE

Immunotherapy Opportunities Lie in Glioma Molecular Landscape

News

A slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be vulnerable to immunotherapy, which gives the immune system a boost in fighting cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE